CD274 and neoplasm: However, these studies do not include the use of second-line–approved antiangiogenic agents such as nintedanib or ramucirumab in combination with docetaxel, and although immunotherapies have shown benefit to those with some degree of expression of PD-L1, the same benefit is not so clear for those with a PD-L1–negative tumor; therefore, additional investigation is required.